Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
February 4, 2015
Wednesday’s RegMed rhythms: too many oversold stalwarts, a warning sign and it’s time to go UP
February 3, 2015
RegMed’s back and forth and that's going to go on for a while
February 3, 2015
Tuesday’s RegMed rhythms: The sector is eager for any news as it could open a window into the timing of any swing to support needed financings
February 2, 2015
RegMed’s message, it is what it is - get on with it
January 28, 2015
RegMed’s risk and volatility is more spontaneous than just emerging
January 28, 2015
Wednesday’s RegMed rhythms: pops, drops and belly flops
January 27, 2015
Tuesday’s RegMed rhythms: forget east coast snow; the sector sells-off and rebounds
January 26, 2015
Monday’s RegMed rhythms: sector turns putting some flesh on its bones
January 23, 2015
Friday’s RegMed rhythms: sector fades more than it blooms
January 22, 2015
Thursday’s RegMed rhythms: door knob investors keep one foot out the exit
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.